Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 3/20 | 0.41 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.41 |
| ▸ | CD22 | P20273 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493295 | 0.95 | NANP (0.47) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL358286 | 0.94 | NANP (0.56) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL284328 | 0.89 | NANP (0.52) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL593858 | 0.89 | NANP (0.52) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL1073940 | 0.89 | NANP (0.52) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL9479903 | 0.88 | NANP (0.51) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL9697921 | 0.86 | NANP (0.59) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL13190787 | 0.85 | NANP (0.67) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL442944 | 0.85 | NANP (0.61) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL420656 | 0.85 | NANP (0.67) | NANPL3MBTL1SELLSELPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029780-B2 | Long-acting polypeptides and methods of producing and administering same | OPKO BIOLOGICS LTD. (IL) | 2024-07-09 | — | — | US | disclosed |
| US-20220241380-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | OPKO BIOLOGICS LTD. (IL) | 2022-08-04 | — | — | US | disclosed |
| US-11197915-B2 | Long-acting polypeptides and methods of producing and administering same | OPKO BIOLOGICS LTD. (IL) | 2021-12-14 | — | — | US | disclosed |
| EP-3763733-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | OPKO Biologics Ltd. (IL) | 2021-01-13 | — | — | EP | disclosed |
| EP-3060239-B1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | OPKO BIOLOGICS LTD (IL) | 2020-05-13 | — | — | EP | disclosed |
| US-20200131242-A1 | METHODS OF TREATMENT WITH LONG-ACTING HORMONE | OPKO BIOLOGICS LTD. (IL) | 2020-04-30 | — | — | US | disclosed |
| US-10351615-B2 | Methods of treatment with long-acting growth hormone | OPKO BIOLOGICS LTD. (IL) | 2019-07-16 | — | — | US | disclosed |
| EP-3482765-A1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | OPKO Biologics Ltd. (IL) | 2019-05-15 | — | — | EP | disclosed |
| US-10221228-B2 | Long-acting polypeptides and methods of producing and administering same | OPKO BIOLOGICS LTD. (IL) | 2019-03-05 | — | — | US | disclosed |
| EP-2739298-B1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | OPKO BIOLOGICS LTD (IL) | 2018-10-03 | — | — | EP | disclosed |
| US-20130184207-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | PROLOR BIOTECH INC. (IL) | 2013-07-18 | — | — | US | disclosed |
| US-8450269-B2 | Long-acting growth hormone and methods of producing same | Prolor Biotech Ltd. (IL) | 2013-05-28 | — | — | US | disclosed |
| US-8426166-B2 | Long-acting polypeptides and methods of producing same | PROLOR BIOTECH INC. (IL) | 2013-04-23 | — | — | US | disclosed |
| WO-2013018098-A2 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | Prolor Biotech Ltd. (IL) | 2013-02-07 | — | — | WO | disclosed |
| US-8304386-B2 | Long-acting growth hormone and methods of producing same | Prolor Biotech, Inc. (IL) | 2012-11-06 | — | — | US | disclosed |
| US-20120035101-A1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT | 2012-02-09 | — | — | US | disclosed |
| US-20120015437-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME | HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT | 2012-01-19 | — | — | US | disclosed |
| US-8048849-B2 | Long-acting polypeptides and methods of producing same | Modigene, Inc. (IL) | 2011-11-01 | — | — | US | disclosed |
| US-20100081614-A1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT | 2010-04-01 | — | — | US | disclosed |
| US-20090312254-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME | HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035101-A1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | IGFBP1, IGFBP5, IGFBP2 | NANP 2576/4885L3MBTL1 4162/4885SELL 1730/4885 |
| US-20120015437-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME | PGF, GNRHR, TSLP | NANP 1835/4885L3MBTL1 4803/4885SELL 636/4885 |
| US-20130184207-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME | PGF, GNRHR, LPXN | NANP 1713/4885L3MBTL1 3708/4885SELL 1333/4885 |
| US-10351615-B2 | Methods of treatment with long-acting growth hormone | IGFBP1, IGFBP5, IGFBP2 | NANP 2621/4885L3MBTL1 3362/4885SELL 2141/4885 |
| US-20090312254-A1 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME | PGF, GNRHR, TSLP | NANP 1835/4885L3MBTL1 4803/4885SELL 636/4885 |
| US-10221228-B2 | Long-acting polypeptides and methods of producing and administering same | PGF, GNRHR, LPXN | NANP 1713/4885L3MBTL1 3708/4885SELL 1333/4885 |
| US-11197915-B2 | Long-acting polypeptides and methods of producing and administering same | GHRHR, CRH, GHSR | NANP 2296/4885L3MBTL1 4739/4885SELL 2432/4885 |
| US-20100081614-A1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | GHRHR, LHCGR, GNRHR | NANP 998/4885L3MBTL1 4591/4885SELL 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.